본문 바로가기
KERD
논문KCI 등재

MAFLD: How is it different from NAFLD?

Ming-Hua Zheng|Jacob George|Cameron Gofton|Yadhavan Upendran
대한간학회 (The korean Association for the Study of the Liver)|2023.04|Clinical and Molecular Hepatology|제29권 제2호|pp. 17-31

4

조회

0

다운로드

10

인용

0

참고문헌

키워드

NAFLDMAFLDMAFLD vs. NAFLD

초록

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.

Abstract

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.

참고문헌 (62)

  1. Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
  2. Bellentani S, "The epidemiology of non-alcoholic fatty liver disease", Liver Int, 37(Suppl 1), pp.81~84 (2017)
  3. Demirtas CO, "Metabolic-associated fatty liver disease : Time to integrate ground-breaking new terminology to our clinical practice?", Hepatol Forum, 1, pp.79~81 (2020)
  4. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
  5. Targher G, "Non-alcoholic fatty liver disease : a multisystem disease requiring a multidisciplinary and holistic approach", Lancet Gastroenterol Hepatol, 6, pp.578~588 (2021)
  6. El-Shabrawi M, "The International Society of Tropical Paediatrics(ISTP)endorses the redefinition of fatty liver disease", J Hepatol, 76, pp.738~739 (2022)
  7. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
  8. Mendez-Sanchez N, "The Latin American Association for the Study of the Liver(ALEH)position statement on the redefinition of fatty liver disease", Lancet Gastroenterol Hepatol, 6, pp.65~72 (2021)
  9. Nan Y, "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease", J Hepatol, 75, pp.454~461 (2021)
  10. Shaltout I, "Arabic Association for the Study of Diabetes and Metabolism(AASD)endorsing the MAFLD definition of fatty liver disease", J Hepatol, 76, pp.739~740 (2022)
  11. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
  12. Takumi Kawaguchi, "MAFLD enhances clinical practice for liver disease in the Asia-Pacific region", Clinical and Molecular Hepatology, 28(2), pp.150~163 (2022), 대한간학회[DOI]
  13. Wang X, "Metabolic Dysfunction-associated Fatty Liver Disease(MAFLD)and Viral Hepatitis", J Clin Transl Hepatol, 10, pp.128~133 (2022)
  14. Younossi ZM, "Are there outcome differences between NAFLD and metabolicassociated fatty liver disease?", Hepatology, 76, pp.1423~1437 (2022)
  15. Alexander M, "Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease", BMC Med, 16, pp.130~ (2018)
  16. Shiha G, "Redefining fatty liver disease : an international patient perspective", Lancet Gastroenterol Hepatol, 6, pp.73~79 (2021)
  17. Nascimbeni F, "From NAFLD in clinical practice to answers from guidelines", J Hepatol, 59, pp.859~871 (2013)
  18. Alem SA, "Capturing patient experience : A qualitative study of change from NAFLD to MAFLD real-time feedback", J Hepatol, 74, pp.1261~1262 (2021)
  19. Clayton M, "From NAFLD to MAFLD : Nurse and allied health perspective", Liver Int, 41, pp.683~691 (2021)
  20. Lim GEH, "An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD", Clin Gastroenterol Hepatol (2021)[DOI]
  21. Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
  22. Zeng J, "Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older : A community-based study", Hepatobiliary Pancreat Dis Int, 21, pp.154~161 (2022)
  23. Zhang YC, "A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population", Hepatol Int, 16, pp.835~845 (2022)
  24. Lazarus JV, "Advancing the global public health agenda for NAFLD: a consensus statement", Nat Rev Gastroenterol Hepatol, 19, pp.60~78 (2022)
  25. Bergqvist CJ, "Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists", Intern Med J, 43, pp.247~253 (2013)
  26. Grant BF, "Barriers to alcoholism treatment : reasons for not seeking treatment in a general population sample", J Stud Alcohol, 58, pp.365~371 (1997)
  27. Staufer K, "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed nonalcoholic fatty liver disease", J Hepatol, 77, pp.918~930 (2022)
  28. Meijnikman AS, "Microbiome-derived ethanol in nonalcoholic fatty liver disease", Nat Med, 28, pp.2100~2106 (2022)
  29. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of alcohol-related liver disease", J Hepatol, 69, pp.154~181 (2018)
  30. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", Obes Facts, 9, pp.65~90 (2016)
  31. Lin S, "Comparison of MAFLD and NAFLD diagnostic criteria in real world", Liver Int, 40, pp.2082~2089 (2020)
  32. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
  33. Yu C, "Comparing the diagnostic criteria of MAFLD and NAFLD in the chinese population : A population-based prospective cohort study", J Clin Transl Hepatol, 10, pp.6~16 (2022)
  34. Wieland AC, "Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk", J Clin Gastroenterol, 49, pp.e6~e10 (2015)
  35. Cleveland ER, "Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample : the CARDIA study", J Gen Intern Med, 34, pp.2772~2778 (2019)
  36. Kawaguchi T, "MAFLD : Renovation of clinical practice and disease awareness of fatty liver", Hepatol Res, 52, pp.422~432 (2022)
  37. Singh A, "Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort", Dig Dis Sci, 65, pp.978~986 (2020)
  38. Tharwat M, "The NAFLD-MAFLD debate through the lens of the Arab world", Saudi J Gastroenterol, 28, pp.413~416 (2022)
  39. Ayada I, "Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis : Focusing on the nonoverlap groups", Liver Int, 42, pp.277~287 (2022)
  40. Baratta F, "Open issues in the transition from NAFLD to MAFLD : The experience of the plinio study", Int J Environ Res Public Health, 18, pp.8993~ (2021)
  41. Kemp W, "Impact of renaming NAFLD to MAFLD in an Australian regional cohort : Results from a prospective population-based study", J Gastroenterol Hepatol, 37, pp.395~403 (2022)
  42. Sinn DH, "Nonalcoholic fatty liver disease without metabolic-associated fatty liver disease and the risk of metabolic syndrome", Clin Gastroenterol Hepatol (2022)[DOI]
  43. Tang A, "Comparative burden of metabolic dysfunction in Lean NAFLD vs Non-lean NAFLD-A systematic review and metaanalysis", Clin Gastroenterol Hepatol (2022)[DOI]
  44. Moon Joon Ho, "Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease", Gut and Liver, 16(3), pp.433~442 (2022), 거트앤리버 소화기연관학회협의회[DOI]
  45. Huang Q, "NAFLD or MAFLD: Which has closer association with all-cause and cause-specific mortality?-Results from NHANES III", Front Med(Lausanne), 8, pp.693507~ (2021)
  46. Muthiah M, "Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease : A longitudinal cohort analysis", Ann Hepatol, 28, pp.100762~ (2022)
  47. Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19, 2172~2181
  48. Semmler G, "Metabolic Dysfunction-Associated Fatty Liver Disease(MAFLD)-Rather a Bystander Than a Driver of Mortality", J Clin Endocrinol Metab, 106, pp.2670~2677 (2021)
  49. Klein S, "Why does obesity cause diabetes?", Cell Metab, 34, pp.11~20 (2022)
  50. Miyake T, "Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus", J Diabetes Investig, 13, pp.1245~1252 (2022)
  51. Niriella MA, "Outcomes of NAFLD and MAFLD : Results from a community-based, prospective cohort study", PLoS One, 16, pp.e0245762~ (2021)
  52. Guerreiro GTS, "Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?", Hepatol Int, 15, pp.380~391 (2021)
  53. Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : A nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
  54. Bessho R, "A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis", PLoS One, 17, pp.e0269265~ (2022)
  55. Sun DQ, "MAFLD and risk of CKD", Metabolism, 115, pp.154433~ (2021)
  56. Miao L, "Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease", J Clin Transl Hepatol, 10, pp.230~237 (2022)
  57. Xue J, "Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with Hepatitis B Virus-related hepatocellular carcinoma based on propensity score matching analysis", Cancer Manag Res, 14, pp.2193~2202 (2022)
  58. Zheng KI, "Clinical utility of the MAFLD definition", J Hepatol, 74, pp.989~991 (2021)
  59. Paternostro R, "Current treatment of non-alcoholic fatty liver disease", J Intern Med, 292, pp.190~204 (2022)
  60. Cheng Han Ng, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name", Clinical and Molecular Hepatology, 28(4), pp.790~801 (2022), 대한간학회
  61. Rinella ME, "Report on the AASLD", EASL joint workshop on clinical trial endpoints in NAFLD, 2019, pp.70, 1424~1436
  62. Fouad Y, "Redefinition of fatty liver disease from NAFLD to MAFLD through the lens of drug development and regulatory science", J Clin Transl Hepatol, 10, pp.374~382 (2022)

관련 논문AI추천

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?Jin-Woo Lee, Korean NAFLD Study Group, Seong Hee Kang, Seung Up Kim, Soung Won Jeong, Yuri Cho대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in nameCheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity김원, Gi-Ae Kim, Joon Ho Moon대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver DiseaseChen Pei-Jer, Huang Shang-Chin, Kao Jia-Horng, Liu Chun-Jen, Su Hau-Jyun, Su Tung-Hung, Tseng Tai-Chung, Yang Hung-Chih거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제3호MAFLD enhances clinical practice for liver disease in the Asia-Pacific regionDan Nakano, Jacob George, Mohammed Eslam, Takuji Torimura, Takumi Kawaguchi, Tsubasa Tsutsumi대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제2호Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology전대원, Eileen Laurel Yoon대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호

이 간행물의 다른 논문 (53건)

Congratulatory remarksSi Hyun Baepp. 1-1Special thanksSeung Up Kimpp. 4-4Global incidence and prevalence of nonalcoholic fatty liver diseaseEunice Tan, Mark D. Muthiah, Cheng Han Ng, Margaret LP Teng, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Daniel Q. Huangpp. 32-42Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyenpp. 86-102Screening strategy for non-alcoholic fatty liver diseaseMan-Fung Yuen, Lung-Yi Mak, Saisai Zhang, Wai-Kay Setopp. 103-122
원문 보기